Patents Assigned to Centre Leon Berard
  • Patent number: 11203641
    Abstract: The subject matter of the present invention relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compound to interact with netrin-1 receptor and/or to inhibit the dimerization of the intracellular domain of the netrin-1 receptor expressed in tumor cells. The invention also relates to a method for predicting the presence of metastatic or aggressive cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of netrin-1. The invention further comprises kits and compounds as a medicament for the treatment of cancer such as metastatic breast cancer, related to the overexpression of netrin-1 by the tumor cells.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: December 21, 2021
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), CENTRE LEON BERARD
    Inventors: Patrick Mehlen, Agnes Bernet, Julien Fitamant
  • Patent number: 11180556
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4? T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: November 23, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, Universite Claude Bernard—Lyon 1, Centre Leon Berard
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
  • Publication number: 20210308491
    Abstract: A therapy apparatus for treating tissue by the emission of focused ultrasound waves, including: a creation surface of a pressure field of focused ultrasound waves divided into at least N sectors having segments of asymmetrical concave curve (S1, S2, . . . ) with centres of curvature; centres of curvature (c1, c2, . . . ) asymmetrical to the extent where the centres of curvature are situated at different distances from the plane of symmetry (A1) or from the axis of symmetry (S) and/or at different depths taken according to the axis of symmetry; the individual axes (a1, a2, . . . ) intersecting between the focal zones (Zc1, Zc2, . . . ) and the creation surface (8) or beyond the focal zones such that the beams originating from the sectors intersect to create a focal coverage zone (Zr) which is off-axis relative to the plane of symmetry (A1) or to the axis of symmetry (S); the sectors of this creation surface (8) creating energy deposit zones with profiles corresponding to the focal coverage zones (Zr).
    Type: Application
    Filed: April 1, 2021
    Publication date: October 7, 2021
    Applicants: EDAP TMS FRANCE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE LEON BERARD
    Inventors: Marine SANCHEZ, David MELO DE LIMA, Jérémy VINCENOT
  • Patent number: 11130817
    Abstract: Provided are antibodies that bind and inhibit CD73, are capable of increasing the proliferation of T cells in the presence of CD39-expressing B cells and ATP. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent cancer.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: September 28, 2021
    Assignees: INNATE PHARMA, CENTRE LÉON BÉRARD
    Inventors: Christophe Caux, Laurent Gauthier, Nicolas Gourdin, Christine Menetrier-Caux, Carine Paturel, Ivan Perrot
  • Publication number: 20210292328
    Abstract: The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing said compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.
    Type: Application
    Filed: September 20, 2017
    Publication date: September 23, 2021
    Applicants: CENTRE LEON BERARD, HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Toufic RENNO, Isabelle COSTE-INVERNIZZI, Stéphane GIRAUD, Serge LEBECQUE
  • Publication number: 20210177755
    Abstract: The present invention relates to a pharmaceutical combination product comprising: a liposomal formulation exclusively containing a LPS; and at least one cytotoxic compound. It also relates to its use as an anti-tumour therapy.
    Type: Application
    Filed: October 30, 2018
    Publication date: June 17, 2021
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1, Hospices Civils de Lyon, Centre Léon Bérard
    Inventors: Charles DUMONTET, Abdelkamel CHETTAB
  • Patent number: 10745482
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4? T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: August 18, 2020
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Institut Jean Paoli & Irene Calmettes, Universite d' Aix-Marseille, Universite Claude Bernard—Lyon 1, Centre Leon Berard
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
  • Patent number: 10633446
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4? T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: April 28, 2020
    Assignees: INSERM (Institut National de la Santéet de la Recherche Medicale), Institut Jean Paoli & Irene Calmettes, Universitéd'Aix-Marseille, Universite Claude Bernerd—Lyon }, Centre Leon Berard
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
  • Patent number: 10533046
    Abstract: The present disclosure relates to a human CK8 antigen peptide, an antibody, or antibody fragment thereof, or a humanized antibody, specifically binding the peptide having the amino acid sequence of SEQ ID No. 29, a fragment of CK-8. Said molecules can be used use in the detection and/or treatment of tumors whose cells express CK8 protein, in particular the peptide of sequence according to SEQ ID No.29, on their surface.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: January 14, 2020
    Assignees: INTERNATIONA—DRUG—DEVELOPMENT—BIOTECH, UNIVERSITE CLAUDE BERNARD LYON 1, HOSPICES CIVILS DE LYON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE LEON BERARD
    Inventors: Marie Alexandra Albaret, Jean-Jacques Diaz, Hichem Claude Mertani, Jean-Christophe Saurin, Claudine Vermot-Desroches, Boris Vuillermoz
  • Patent number: 10485516
    Abstract: Method for generating a shear wave in a target region of a soft solid, includes the following steps: a) generating at least two shear waves with a first and a second source of shear waves in the target region; b) detecting a propagation pattern of the shear wave in the target region with a detector unit including a row of ultrasonic transducers aligned on a first direction perpendicular to a detection direction of each or a single ultrasonic transducer movable along a first direction perpendicular to its detection direction; c) proceeding to a time reversal of the detected propagation pattern; and d) submitting the target region to an inverted excitation set of forces based on the temporally inverted propagation pattern. During step b), a first propagation pattern is detected when only the first source is active and a second propagation pattern is detected when only the second source is active.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: November 26, 2019
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Université Claude Bernard Lyon 1, Centre Léon-Bérard
    Inventors: Stefan Catheline, Remi Souchon, Ali Zorgani, Jean-Yves Chapelon
  • Patent number: 10273306
    Abstract: The invention relates to a specific antibody directed against, for use for treating graft versus host disease.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: April 30, 2019
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Centre Leon Berard, Université d' Aix-Marseille
    Inventors: Gilles Marodon, Daniel Olive, Christine Menetrier-Caux
  • Patent number: 10197578
    Abstract: A method for predicting cellular, tissular, and clinical radiosensitivity, based on the determination and correlation of several cellular and enzymatic parameters.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: February 5, 2019
    Assignees: UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE LEON BERARD, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Nicolas Foray, Adeline Granzotto, Clément Devic
  • Publication number: 20190030126
    Abstract: The present invention relates to a competitive inhibitor of the binding of the protein Bcl-2 L10 to the ligand binding domain of at least one of the IP3R receptors, for its use in the treatment of cancers, the cells of which express the protein Bcl-2 L10.
    Type: Application
    Filed: March 8, 2017
    Publication date: January 31, 2019
    Applicants: Universite Claude Bernard - Lyon 1, Centre Leon Berard, Centre National de la Recherche Scientifique (CNRS ), Institut National de la Sante et de la Recherche M edicale (INSERM)
    Inventors: Adrien Nougarede, Ruth Rimokh, Germain Gillet, Nikolay Georgiev
  • Patent number: 10180437
    Abstract: A method for predicting cellular, tissue and clinical radiosensitivity, which is based on the determination and correlation of multiple parameters and cellular and enzymatic criteria.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: January 15, 2019
    Assignees: UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE LEON BERARD, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Nicolas Foray, Adeline Granzotto, Clément Devic
  • Publication number: 20180291106
    Abstract: The subject matter of the present invention relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compound to interact with netrin-1 receptor and/or to inhibit the dimerization of the intracellular domain of the netrin-1 receptor expressed in tumor cells. The invention also relates to a method for predicting the presence of metastatic or aggressive cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of netrin-1. The invention further comprises kits and compounds as a medicament for the treatment of cancer such as metastatic breast cancer, related to the overexpression of netrin-1 by the tumor cells.
    Type: Application
    Filed: June 21, 2018
    Publication date: October 11, 2018
    Applicants: Centre National de la Recherche Scientifique (CNRS), Centre Leon Berard
    Inventors: Patrick Mehlen, Agnes Bernet, Julien Fitamant
  • Publication number: 20180238859
    Abstract: A predictive method of cellular, tissue and clinical radiosensitivity, which is based on the determination and cross-checking of a plurality of cellular and enzymatic parameters and criteria applied to a tumor response. The predictive method characterizes the sensitivity of a tumor in response to a DNA-breaking radiotherapy treatment.
    Type: Application
    Filed: August 16, 2016
    Publication date: August 23, 2018
    Applicants: NEOLYS DIAGNOSTICS, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, CENTRE LEON BERARD, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE CLAUDE BERNARD LYON 1
    Inventors: Nicolas FORAY, Larry BODGI, Sandrine PEREIRA
  • Patent number: 10004888
    Abstract: The method determines parameters to generate confocal ultrasound beams (B1,B2) inside a medium (4), and uses a device (1) comprising first and second ultrasound means (11,12) and first and second displacement members (13,14) for moving the ultrasound means (11,12). The parameters include signals s1,s2 to the ultrasound means (11,12), and the positions x1,x2 of the ultrasound means (11,12). The parameters are optimized for having a minimum amplitude a1,a2 of the signals s1,s2 and having an acoustic effect inside the medium (4).
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: June 26, 2018
    Assignees: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE CLAUDE BERNARD, CENTRE LÉON BÉRARD
    Inventors: Jean-Yves Chapelon, Cyril Lafon, Jean-Louis Mestas
  • Patent number: 9975950
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: May 22, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, Universite Claude Bernard—Lyon 1, Centre Leon Berard
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
  • Patent number: 9695247
    Abstract: The invention relates to a specific antibody directed against, for use for treating graft versus host disease.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: July 4, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE LEON BERARD, UNIVERSITÉ D'AIX-MARSEILLE
    Inventors: Gilles Marodon, Daniel Olive, Christine Menetrier-Caux
  • Patent number: 9683986
    Abstract: A method for selecting in vitro compounds is capable of potentiating the effect of a DNA damage inducing chemotherapy agent for the treatment of cancer, and includes selecting compounds inhibiting the interaction between MyD88 and ERK MAP KINASE.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: June 20, 2017
    Assignees: CENTRE LEON BERARD, UNIVERSITE CLAUDE BERNARD LYON 1, HOSPICES CIVILS DE LYON, INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Alain Kfoury, Isabelle Coste-Invernizzi, Serge Lebecque, Toufic Renno